Malignant hyperthermia (MH) is a state of elevated skeletal muscle metaboli
sm that may occur during general anaesthesia in genetically pre-disposed in
dividuals. Malignant hyperthermia results from altered control of sarcoplas
mic reticulum (SR) Ca2+ release. Mutations have been identified in MH-susce
ptible (MHS) individuals in two key proteins of excitation-contraction (EC)
coupling, the Ca2+ release channel of the SR, ryanodine receptor type 1 (R
yR1) and the alpha1-subunit of the dihydropyridine receptor (DHPR, L-type C
a2+ channel). During EC coupling, the DHPR senses the plasma membrane depol
arization and transmits the information to the ryanodine receptor (RyR). As
a consequence, Ca2+ is released from the terminal cisternae of the SR. One
of the human MH-mutations of RyR1 (Arg614Cys) is also found at the homolog
ous location in the RyR of swine (Arg615Cys). This animal model permits the
investigation of physiological consequences of the homozygously expressed
mutant release channel. Of particular interest is the question of whether v
oltage-controlled release of Ca2+ is altered by MH-mutations in the absence
of MH-triggering substances. This question has recently been addressed in
this laboratory by studying Ca2+ release under voltage clamp conditions in
both isolated human skeletal muscle fibres and porcine myotubes.